Breaks Categories: News

WednesdayAug 19, 2020 10:40 am

BioMedNewsBreaks – Shares of DarioHealth Corp. (NASDAQ: DRIO) Reach 52-Week High

Shares of DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, reached a new 52-week high on Wednesday. In morning trading, the company’s shares reached a peak of $22.49 on volume of over 170,000, up from an opening price of $18.75. At time of publishing, shares of DRIO hover around $21.35, marking a PPS increase of roughly 13.87% on the day. About DarioHealth Corp. DarioHealth Corp. is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the…

Continue Reading

TuesdayAug 18, 2020 11:48 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Sale of 8 Skyline Medical STREAMWAY(R) Systems to Large University Hospital Organization

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY(R) System for automated, direct-to-drain medical fluid disposal, has completed the sale of eight systems to a large university hospital organization in Virginia for a new surgical center. According to the update, the organization already has two STREAMWAY systems currently in use. The sale is expected to generate approximately 4,000 annual procedures. To view the full press release, visit http://ibn.fm/mzHmo About Predictive Oncology Inc. Predictive Oncology operates through…

Continue Reading

MondayAug 17, 2020 2:05 pm

BioMedNewsBreaks – Aegis Capital Corp. Initiates Coverage, Issues ‘Buy’ Rating on DarioHealth Corp. (NASDAQ: DRIO)

Aegis Capital Corp. has initiated coverage with a ‘Buy’ rating and price target of $25 on shares of DarioHealth’s (NASDAQ: DRIO) stock. DRIO is a pioneer in the global digital therapeutics (“DTx”) industry with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The report reads, “We initiate coverage on DRIO with a BUY rating and $25 PT based on a 5.6x EV/Sales multiple applied to FY:21E sales of $11.4mm, a discount to the est. peer average of 8.1x. We believe this multiple is warranted thanks to the growth prospects and quality of the product offering, underpinned by published efficacy…

Continue Reading

MondayAug 17, 2020 10:49 am

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Engages LaunchWorks for Commercial Release of MiQLab(TM)

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has engaged LaunchWorks to support the commercial launch of MiQLab(TM) prior to the end of September 2020. “We are making great progress in adding sales and manufacturing to LexaGene’s capabilities. I’m very pleased to announce our partnership with LaunchWorks, which will be responsible for manufacturing the consumables required to operate MiQLab,” Dr. Jack Regan, LexaGene’s CEO and Founder, stated in the news release. “Launchworks can currently manufacture enough products to easily support our commercial launch and have the…

Continue Reading

FridayAug 14, 2020 11:12 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q2 2020 Results, Business Update and DojoLIVE! Interview

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Thursday released financial results for the quarter ended June 30, 2020 and provided a business update. “During the second quarter we reached a major milestone in our journey towards full commercialization with the first sale of our novel ovarian cancer cell media to a top-rated medical university in New England,” Dr. Carl Schwartz, Predictive Oncology CEO, stated in the news release. "This sale serves as a solid proof point of our mission and is a significant achievement towards improving healthcare…

Continue Reading

WednesdayAug 12, 2020 12:07 pm

BioMedNewsBreaks – FWD Pharma 2020 to Shine Spotlight on Impactful Digital Trends in Today’s Shifting Landscape

Lincoln Health Network’s second annual FWD Pharma Conference is set to draw an engaging lineup of marketing and brand practitioners from leading organizations and shine the spotlight on biotech and life-science strategies in a complex digital world. Slated to be held Aug. 31-Sept. 1, 2020, the event promises to amplify attendees’ digital transformation of commercial operations and market access through omnichannel engagements, campaign analytics and marketing automation. FWD Pharma 2020 will feature keynotes, interactive panels, case studies, hands-on workshops, and peer-to-peer learning opportunities. A diverse group of marketing and brand practitioners from leading life-sciences organizations will share successful strategies to…

Continue Reading

WednesdayAug 12, 2020 10:27 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Q2 Revenue, Overview of Key Company Highlights and Development

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has released a business update, including financial numbers and corporate achievements for the second quarter ended June 30, 2020. Highlights of the report include the company’s announcement of two Remote Patient Monitoring (“RPM”) agreements in the United States as well as an agreement with Williams Medical, which allowed Dario to enter the United Kingdom. In addition, the company reported Q2 revenues of $1.79 million, a 7.2% sequential increase from Q1 2020. "The COVID-19 pandemic has accelerated our ongoing transformation to a business-to-business-to-consumer (B2B2C) digital therapeutics leader," said Dario CEO Erez…

Continue Reading

TuesdayAug 11, 2020 11:01 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Shareholder Letter Highlights Achievements, Discusses Two Key Proposals

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, outlined the company’s recent accomplishments in a letter released to shareholders. The letter, sent from CEO Dr. Carl Schwartz, also summarized voting recommendations from POAI’s Board of Directors regarding two proposals that are scheduled for shareholder vote next month. “Predictive Oncology is committed to executing our strategic vision to develop and commercialize an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value for our shareholders,” stated Schwartz in a press release containing…

Continue Reading

MondayAug 10, 2020 2:41 pm

BioMedNewsBreaks – BioMedWire to Serve as Official Newswire for FWD Pharma Conference and Strategic HCP Partnerships Summit

BioMedWire ("BMW"), a specialized communications platform for the life sciences sector and one of many brands part of the InvestorBrandNetwork (“IBN”), today announced its collaboration with the FWD Pharma Conference, scheduled to be held Aug. 31-Sept. 1, 2020, as well as participation in the Strategic HCP Partnerships Summit, slated for Nov. 18-20, 2020. According to the update, IBN will serve as the official media sponsor and BioMedWire will serve as the official newswire of both events. “We have enjoyed working with the Global Strategic Management Institute on multiple events in the past and are looking forward to continuing that relationship,”…

Continue Reading

MondayAug 10, 2020 11:32 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Featured in Fox Business Segment Regarding Telehealth and the Future

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, was featured in a Fox Business segment on Friday titled, “Is telehealth the future of health care?” Dariohealth CEO Erez Raphael joined Fox’s Liz Claman to explain where he sees digital health and digital therapeutics going from here. “In order to treat chronic conditions, it’s very, very important to surround the user 24/7, and digital solutions and digital therapeutic solutions, such as Livongo, is a solution for chronic condition management,” Raphael stated, referring to Livongo Health Inc.’s (NASDAQ: LVGO) solution in a recent collaboration with Teladoc Health Inc. (NYSE:…

Continue Reading